PDF herunterladen
Drug Res (Stuttg) 2013; 63(11): 602
DOI: 10.1055/s-0033-1357211
Erratum
© Georg Thieme Verlag KG Stuttgart · New York

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

B. Bittner
1   F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
2   F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland
,
W. F. Richter
3   F. Hoffmann-La Roche Ltd., Nonclinical Safety, Basel, Switzerland
,
F. Hourcade-Potelleret
4   F. Hoffmann-La Roche Ltd., Clinical Modeling & Simulation, Basel, Switzerland
,
C. McIntyre
1   F. Hoffmann-La Roche Ltd., Clinical Pharmacology, Basel, Switzerland
,
F. Herting
5   Roche Diagnostics GmbH, Penzberg, Germany
,
M. L. Zepeda
6   Halozyme Therapeutics Inc., San Diego, CA, USA
,
J. Schmidt
2   F. Hoffmann-La Roche Ltd., Pharma Medicines Global Product Strategy, Basel, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. Oktober 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Originalartikel zu diesem Erratum:

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing RegimenArzneimittelforschung 2012; 62(09): 401-409
DOI: 10.1055/s-0032-1321831

Erratum

Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen

B. Bittner, W. F. Richter, F. Hourcade-Potelleret, C. McIntyre, F. Herting, M. L. Zepeda, J. Schmidt

Arzneimittelforschung 2012; 62: 401–409

DOI: 10.1055/s-0032-1321831

The references referring to other sections like “Section 6.4“ are no longer valid as the new formatting removed the numbers for the different paragraphs in the article.